Tobacco and Public Health - TCSC Indonesia

200
NICOTINE DOSING CHARACTERISTICS ACROSS TOBACCO PRODUCTS
own brands, low-nitrosamine cigarettes produced similar withdrawal suppression and
heart rate increase and higher plasma nicotine concentrations (Breland et al. 2002b).
These three studies represent the limited state of the non-tobacco industry funded
published literature in that they are far too small to develop conclusions regarding the
products tested.
References
Adams, J. D., O’Mara-Adams, K. J., and Hoffmann, D. (1987). Toxic and carcinogenic agents in
undiluted mainstream smoke and sidestream smoke of different types of cigarettes.
Carcinogenesis, 8, 729–31.
Baker, R. R. (2002). The development and significance of standards for smoking-machine methodology.
Beitr. Tabakforsch., Intl., 20, 23–41.
Benowitz, N. L. (1998a). Nicotine pharmacology and addiction. In: Nicotine safety and toxicology
(ed. N. L. Benowitz), pp. 3–16. Oxford University Press.
Benowitz, N. L. (1998b). Cardiovascular toxicity of nicotine: pharmacokinetic and pharmacodynamic
considerations. In: Nicotine safety and toxicology (ed. N. L. Benowitz), pp. 19–28. Oxford
University Press.
Benowitz, N. L., Jacob, P. J., III, and Slade, J. (1997). Nicotine content of the Eclipse nicotine delivery
device. Am.J.Publ. Health, 87, 1865–6.
Benowitz, N. (1999). Nicotine addiction. Primary Care, 26, 611–31.
Borgerding, M. F., Bodnar, J. A., Chung, H. L., Mangan, P. P., Morrison, C. C., Risner, C. H., et al. (1997).
Chemical and biological studies of a new cigarette that primarily heats tobacco. Part I. Chemical
composition of mainstream smoke. Fd. Chem. Toxicol., 36, 169–82.
Borgerding, M. F., Bodnar, J. A., and Wingate, D. E. (2000). The 1999 Massachusetts Benchmark
Study—Final Report (2000). A research study conducted after consultation with the
Massachusetts Department of Health.
Bradford, J. A., Harlan, W. R., and Hanmer, H. R. (1936). Nature of cigarette smoke. Technic of
experimental smoking. Ind. Engi. Chem., 28, 836–9.
Breland, A. B., Buchhalter, A. R., Evans, S. E., and Eissenberg, T. (2002a). Evaluating acute effects of
potential reduced-exposure products for smokers: Clinical laboratory methodology. Nicotine &
Tobacco Research, S131–S140
Breland, A. B., Evans, S. E., Buchhalter, A. R., and Eissenberg, T. (2002b). Accute effects of
AdvanceTM :A potential reduced exposure product for smokers. Tob Contr. 11, 376–8.
Breland, A. B., Acosta, M. C., and Eissenberg, T. (2003). Tobacco-specific nitrosamines and potential
reduced exposure products for smokers: Preliminary evaluation of AdvanceTM (Submitted for
publication).
Brunnemann, K. D., Hoffmann, D., Garioala, C. G., and Lee, B. C. (1994). Low ignition propensity
cigarettes: Smoke analysis for carcinogens and testing for mutagenic activity of the smoke
particulate matter. Fd. Chem. Toxicol., 32, 917–22.
Brunnemann, K. D., Mitacek, E. J., Liu, Y., Limsila, T., and Suttaajit, M. (1996). Assessment of major
carcinogenic tobacco-specific nitrosamines in Thai cigarettes. Cancer Detection & Prevention,
20, 114–21.
Burns, D. M. and Benowitz, N. L. (2001). Public health implication of changes in cigarette design and
marketing. In: Smoking and tobacco control monograph no. 13: Risks associated with smoking cigarettes
with low machine-measured yields of tar and nicotine.U.S. Department of Health and Human
Services. Public Health Service. National Institutes of Health, National Cancer Institute, pp. 1–12.